TLSA
Tiziana Life Sciences Ltd.
NASDAQ · Healthcare · Biotechnology · GB
$0.90
−0.52%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 21.2M | — | — | — | 14.6M |
| Gross Profit | (21.2M) | — | — | — | (14.6M) |
| Operating Expenses | |||||
| R&D Expense | 9.7M | 10.3M | 5.2M | 8.1M | — |
| SG&A Expense | 5.9M | 10.9M | 10.6M | 9.9M | — |
| General & Admin Expense | — | 10.9M | 10.6M | 9.9M | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 4.9M | — | — | — | — |
| Total Operating Expenses | 20.6M | 21.1M | 15.8M | 18.0M | — |
| Cost and Expenses | 41.8M | 21.1M | 15.8M | 18.0M | 14.6M |
| Operating Income (EBIT) | (41.8M) | (21.1M) | (15.8M) | (18.0M) | (14.6M) |
| Non-Operating | |||||
| Interest Income | 707.0K | 19.0K | 814.0K | 1.2M | — |
| Interest Expense | 6.0K | 18.0K | 6.0K | 10.0K | 7.0K |
| Net Interest Income | 701.0K | 1.0K | 808.0K | 1.1M | (7.0K) |
| Other Non-Op Income/Expense | 2.2M | 2.7M | (952.0K) | 742.0K | (811.0K) |
| Non-Operating Income (excl Interest) | (2.2M) | (2.7M) | 946.0K | (752.0K) | 804.0K |
| EBT (Pre-Tax Income) | (39.6M) | (18.4M) | (16.7M) | (17.2M) | (15.4M) |
| Income Tax Expense | (1.6M) | — | (4.9M) | 449.0K | — |
| Bottom Line | |||||
| Net Income | (38.0M) | (18.4M) | (11.9M) | (17.7M) | (15.4M) |
| Earnings from Cont. Ops | (38.0M) | (18.4M) | (11.9M) | (17.7M) | (15.4M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (38.0M) | (18.4M) | (11.9M) | (17.7M) | (15.4M) |
| Per Share | |||||
| Basic EPS | ($0.32) | ($0.16) | ($0.11) | ($0.17) | ($0.15) |
| Diluted EPS | ($0.32) | ($0.16) | ($0.11) | ($0.17) | ($0.15) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 127.9M | 118.3M | 106.7M | 102.5M | 101.5M |
| Diluted Shares Outstanding | 127.9M | 118.3M | 106.7M | 102.5M | 101.5M |
| Profitability Metrics | |||||
| EBITDA | (39.1M) | (18.2M) | (16.6M) | (17.1M) | (15.3M) |
| D&A | 454.0K | 234.0K | 124.0K | 96.0K | 51.0K |
| EBIT | (39.6M) | (18.4M) | (16.7M) | (17.2M) | (15.4M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026